Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging
Paragangliomas are neural crest-derived tumors, arising either from chromaffin sympathetic tissue (in adrenal, abdominal, intra-pelvic or thoracic paraganglia) or from parasympathetic tissue (in head and neck paraganglia). They have a specific cellular metabolism, with the ability to synthesize, sto...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2012-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2011.00058/full |
| _version_ | 1819019612833972224 |
|---|---|
| author | Elise M Blanchet Victoria eMartucci Karel ePacak |
| author_facet | Elise M Blanchet Victoria eMartucci Karel ePacak |
| author_sort | Elise M Blanchet |
| collection | DOAJ |
| description | Paragangliomas are neural crest-derived tumors, arising either from chromaffin sympathetic tissue (in adrenal, abdominal, intra-pelvic or thoracic paraganglia) or from parasympathetic tissue (in head and neck paraganglia). They have a specific cellular metabolism, with the ability to synthesize, store and secrete catecholamines (although most head and neck paragangliomas do not secrete any catecholamines). This disease is rare and also very heterogeneous, with various presentations (e.g., in regards to localization, multifocality, potential to metastasize, biochemical phenotype, and genetic background). With growing knowledge, notably about the pathophysiology and genetic background, guidelines are evolving rapidly. In this context, functional imaging is a challenge for the management of paragangliomas.Nuclear imaging has been used for exploring paragangliomas for the last three decades, with MIBG historically as the first-line exam. Tracers used in paragangliomas can be grouped in three different categories. Agents that specifically target catecholamine synthesis, storage, and secretion pathways include: 123 and 131I-metaiodobenzylguanidine (123/131I-MIBG), 18F-fluorodopamine (18F-FDA), and 18F-fluorodihydroxyphenylalanine (18F-FDOPA). Agents that bind somatostatin receptors include 111In-pentetreotide and 68Ga-labelled somatostatin analog peptides. The non-specific agent most commonly used in paragangliomas is 18F-fluorodeoxyglucose (18F-FDG). This review will first describe conventional scintigraphic exams that are used for imaging paragangliomas. In the second part we will emphasize the interest in new PET approaches (specific and non-specific), considering the growing knowledge about genetic background and pathophysiology, with the aim of understanding how tumors behave, and optimally adjusting imaging technique for each tumor type. |
| first_indexed | 2024-12-21T03:38:05Z |
| format | Article |
| id | doaj.art-8f7ce339b7e74fc5be982a26cf3d232e |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-21T03:38:05Z |
| publishDate | 2012-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-8f7ce339b7e74fc5be982a26cf3d232e2022-12-21T19:17:16ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2012-01-01110.3389/fonc.2011.0005816042Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular ImagingElise M Blanchet0Victoria eMartucci1Karel ePacak2Centre Hospitalier d'AngersNational Institutes of HealthNational Institutes of HealthParagangliomas are neural crest-derived tumors, arising either from chromaffin sympathetic tissue (in adrenal, abdominal, intra-pelvic or thoracic paraganglia) or from parasympathetic tissue (in head and neck paraganglia). They have a specific cellular metabolism, with the ability to synthesize, store and secrete catecholamines (although most head and neck paragangliomas do not secrete any catecholamines). This disease is rare and also very heterogeneous, with various presentations (e.g., in regards to localization, multifocality, potential to metastasize, biochemical phenotype, and genetic background). With growing knowledge, notably about the pathophysiology and genetic background, guidelines are evolving rapidly. In this context, functional imaging is a challenge for the management of paragangliomas.Nuclear imaging has been used for exploring paragangliomas for the last three decades, with MIBG historically as the first-line exam. Tracers used in paragangliomas can be grouped in three different categories. Agents that specifically target catecholamine synthesis, storage, and secretion pathways include: 123 and 131I-metaiodobenzylguanidine (123/131I-MIBG), 18F-fluorodopamine (18F-FDA), and 18F-fluorodihydroxyphenylalanine (18F-FDOPA). Agents that bind somatostatin receptors include 111In-pentetreotide and 68Ga-labelled somatostatin analog peptides. The non-specific agent most commonly used in paragangliomas is 18F-fluorodeoxyglucose (18F-FDG). This review will first describe conventional scintigraphic exams that are used for imaging paragangliomas. In the second part we will emphasize the interest in new PET approaches (specific and non-specific), considering the growing knowledge about genetic background and pathophysiology, with the aim of understanding how tumors behave, and optimally adjusting imaging technique for each tumor type.http://journal.frontiersin.org/Journal/10.3389/fonc.2011.00058/fullRadionuclide Imagingpositron emission tomography18F-fluorodeoxyglucose18F-fluorodopamine18F-fluorodyhydroxyphenylalaninegenetic mutation |
| spellingShingle | Elise M Blanchet Victoria eMartucci Karel ePacak Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging Frontiers in Oncology Radionuclide Imaging positron emission tomography 18F-fluorodeoxyglucose 18F-fluorodopamine 18F-fluorodyhydroxyphenylalanine genetic mutation |
| title | Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging |
| title_full | Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging |
| title_fullStr | Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging |
| title_full_unstemmed | Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging |
| title_short | Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging |
| title_sort | pheochromocytoma and paraganglioma current functional and future molecular imaging |
| topic | Radionuclide Imaging positron emission tomography 18F-fluorodeoxyglucose 18F-fluorodopamine 18F-fluorodyhydroxyphenylalanine genetic mutation |
| url | http://journal.frontiersin.org/Journal/10.3389/fonc.2011.00058/full |
| work_keys_str_mv | AT elisemblanchet pheochromocytomaandparagangliomacurrentfunctionalandfuturemolecularimaging AT victoriaemartucci pheochromocytomaandparagangliomacurrentfunctionalandfuturemolecularimaging AT karelepacak pheochromocytomaandparagangliomacurrentfunctionalandfuturemolecularimaging |